MGRM · As filed with the SEC
Monogram Technologies cash flow statement, by quarter
The statement as Monogram Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) · USD
| USD | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023 3 months ended Dec 31, 2023 | Q3 2023 3 months ended Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating activities: | ||||||||
| Net loss | — | (3,188,000) | — | — | — | (3,506,704) | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | — | 292,000 | — | — | — | 294,899 | — | — |
| Other expenses settled with stock issuances | — | — | — | — | — | 37,500 | — | — |
| Loss from change in fair value of common stock make-whole obligation | — | — | — | — | — | 45,252 | — | — |
| Depreciation and amortization | — | 108,000 | — | — | — | 105,898 | — | — |
| Changes in non-cash working capital balances: | ||||||||
| Account receivable | — | — | — | — | — | 364,999 | — | — |
| Other current assets | — | 41,000 | — | — | — | (111,445) | — | — |
| Accounts payable | — | 13,000 | — | — | — | (1,140,955) | — | — |
| Accrued liabilities | — | 421,000 | — | — | — | 258,303 | — | — |
| Operating lease assets and liabilities, net | — | (1,000) | — | — | — | 1,485 | — | — |
| Cash used in operating activities | — | (2,314,000) | — | — | — | (3,650,768) | — | — |
| Investing activities: | ||||||||
| Purchases of equipment | — | (156,000) | — | — | — | (11,389) | — | — |
| Cash used in investing activities | — | (156,000) | — | — | — | (11,389) | — | — |
| Financing activities: | ||||||||
| Proceeds from issuances of Common Stock, net of cash costs | — | 0 | — | — | — | 150,702 | — | — |
| Proceeds from warrant exercises | — | 82,000 | — | — | — | — | — | — |
| Cash provided by financing activities | — | 82,000 | — | — | — | 150,702 | — | — |
| Decrease in cash and cash equivalents during the period | — | (2,388,000) | — | — | — | (3,511,455) | — | — |
| Cash and cash equivalents, beginning of the period | 13,270,000 | 15,658,000 | 16,565,142 | 7,306,000 | 10,078,000 | 13,589,028 | 14,875,476 | 17,097,675 |
| Cash and cash equivalents, end of the period | 12,834,000 | 13,270,000 | 15,658,000 | 16,565,142 | 7,306,069 | 10,077,573 | 13,589,028 | 14,875,476 |
| Noncash investing and financing activities: | ||||||||
| Amortization of deferred issuance costs of Common Stock Purchase Agreement | — | — | — | — | — | 145,956 | — | — |
| Series D Preferred Stock dividends settled through issuance of Common Stock | — | 201,000 | — | — | — | — | — | — |
| Cashless exercise of warrant | — | — | — | — | — | 246 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.